Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis.
The authors studied the safety and tolerability of subcutaneous interferon beta-1a at different doses in 24 children with clinically definite multiple sclerosis. After a mean treatment period of 44 months, interferon beta-1a was well tolerated in 22 patients, although two experienced possible serious adverse events. Although effectiveness cannot be inferred from this study, the authors did observe a significant reduction in the relapse rate at 22 mug, three times weekly, in the relapsing-remitting subgroup.
Tenembaum
Silvia N
SN
Department of Neurology, Hospital de Pediatria Prof. Dr. Juan P. Garrahan, Buenos Aires, Argentina. solier@ciudad.com.ar
Segura
Martin J
MJ
D000293:Adolescent; D017668:Age of Onset; D002648:Child; D005260:Female; D006801:Humans; D007167:Immunotherapy; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000276:immunology / Q000627:therapeutic use*; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology; D011446:Prospective Studies; D016896:Treatment Outcome
D016899:Interferon-beta; D000068556:Interferon beta-1a